Literature DB >> 637594

Alterations in plasma and CSF amino acids, amines and metabolites in hepatic coma.

A R Smith, F Rossi-Fanelli, V Ziparo, J H James, B A Perelle, J E Fischer.   

Abstract

The dog with an end-to-side portacaval shunt (PCS) has been extensively used as a model to investigate hepatic encephalopathy (HE) as it demonstrates a plasma amino acid pattern similar to patients with chronic liver disease. In adult mongrel dogs, the effect of PCS on plasma and CSF amino acids, octopamine (OCT), phenylethanolamine (PEA) and CSF 5-hydroxyindolacetic acid (5-HIAA), were studied. Moreover, the effect of correction of plasma amino acids by infusional techniques was investigated.Tyrosine, tryptophan and phenylalanine levels increased dramatically during the development of HE in plasma and CSF, while valine, leucine and isoleucine decreased in plasma only, but CSF levels remained stable. Plasma and CSF octopamine and phenylethanolamine and CSF 5-HIAA increased markedly as clinical features in the dogs' behavior, characteristic of hepatic encephalopathy occurred, including hypersalivation, ataxia, flapping tremor, somnolence and finally coma. Once in coma, the dogs were infused with an amino acid mixture (F080) calculated to normalize the plasma amino acid pattern. After one to eight hours, the dogs began to awake. Simultaneously, blood, and CSF aromatic amino acids returned to their control values, as did OCT, PEA and CSF 5-HIAA. If F080 infusion was stopped, biochemical alterations would appear within one week, again accompanied by clinical hepatic encephalopathy.The results indicate that the altered levels of aromatic and branched chain amino acids, octopamine and PEA in plasma and CSF correlate well with the development of HE and that correction of the plasma amino acid abnormalities improves encephalopathy simultaneously with correction of neurotransmitter derangements in CSF.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 637594      PMCID: PMC1396425          DOI: 10.1097/00000658-197803000-00024

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  29 in total

1.  [EFFECT OF SHORT-CHAIN FATTY ACIDS ON THE ELECTRICAL ACTIVITY OF THE NEO-, PALEO-, AND ARCHICORTICAL SYSTEM].

Authors:  Y MUTO; Y TAKAHASHI; H KAWAMURA
Journal:  No To Shinkei       Date:  1964-07

2.  Methionine toxicity in liver disease and its prevention by chlortetracycline.

Authors:  E A PHEAR; B RUEBNER; S SHERLOCK; W H SUMMERSKILL
Journal:  Clin Sci       Date:  1956-02       Impact factor: 6.124

3.  Regional brain indoleamine metabolism following chronic portacaval anastomosis in the rat.

Authors:  M G Cummings; P B Soeters; J H James; J M Kean; J E Fischer
Journal:  J Neurochem       Date:  1976-08       Impact factor: 5.372

Review 4.  False adrenergic transmitters.

Authors:  I J Kopin
Journal:  Annu Rev Pharmacol       Date:  1968       Impact factor: 13.820

5.  False neurotransmitters and hepatic failure.

Authors:  J E Fischer; R J Baldessarini
Journal:  Lancet       Date:  1971-07-10       Impact factor: 79.321

6.  An enzymatic assay for octopamine and other beta-hydroxylated phenylethylamines.

Authors:  P B Molinoff; L Landsberg; J Axelrod
Journal:  J Pharmacol Exp Ther       Date:  1969-12       Impact factor: 4.030

7.  Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.

Authors:  W H Oldendorf
Journal:  Am J Physiol       Date:  1971-12

8.  Insulin, glucagon, aminoacid imbalance, and hepatic encephalopathy.

Authors:  P B Soeters; J E Fischer
Journal:  Lancet       Date:  1976-10-23       Impact factor: 79.321

9.  Gamma-glutamyl transpeptidase in brain capillaries: possible site of a blood-brain barrier for amino acids.

Authors:  M Orlowski; G Sessa; J P Green
Journal:  Science       Date:  1974-04-05       Impact factor: 47.728

10.  Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy.

Authors:  C O Record; B Buxton; R A Chase; G Curzon; I M Murray-Lyon; R Williams
Journal:  Eur J Clin Invest       Date:  1976-09-10       Impact factor: 4.686

View more
  35 in total

1.  Augmented sensitivity to benzodiazepine in septic shock rats.

Authors:  T Komatsubara; Y Kadoi; S Saito
Journal:  Can J Anaesth       Date:  1995-10       Impact factor: 5.063

Review 2.  Branched chain amino acids in liver disease: fact or fantasy?

Authors:  D B Silk
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

3.  Amino acids in hepatic coma.

Authors:  J E Fischer
Journal:  Dig Dis Sci       Date:  1982-02       Impact factor: 3.199

Review 4.  Pathogenesis of hepatic encephalopathy.

Authors:  L Zieve
Journal:  Metab Brain Dis       Date:  1987-09       Impact factor: 3.584

Review 5.  Progress in the treatment of chronic portasystemic encephalopathy.

Authors:  I R Crossley; R Williams
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

Review 6.  Parenteral nutrition: current status and concepts.

Authors:  G D Phillips; C L Odgers
Journal:  Drugs       Date:  1982-04       Impact factor: 9.546

7.  Effect of total hepatectomy and administration of branched-chain amino acids on regional norepinephrine, dopamine, and amino acids in rat brain.

Authors:  P M Herlin; J H James; C A Nachbauer; J E Fischer
Journal:  Ann Surg       Date:  1983-08       Impact factor: 12.969

8.  [Tryptophan metabolism in liver diseases: a pharmacokinetic and enzymatic study].

Authors:  M Rössle; R Herz; B Klein; W Gerok
Journal:  Klin Wochenschr       Date:  1986-07-01

9.  Amino acid, ammonia and neurotransmitter concentrations in hepatic encephalopathy: serial analysis in plasma and cerebrospinal fluid during treatment with an adapted amino acid solution.

Authors:  M Rössle; M Luft; R Herz; B Klein; M Lehmann; W Gerok
Journal:  Klin Wochenschr       Date:  1984-09-17

10.  Changes in pituitary secretion after administration of branched-chain amino acids to patients with hepatic cirrhosis.

Authors:  T Barreca; R Franceschini; V Messina; P Bottaro; E Rolandi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.